REGN:NSD-Regeneron Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 567.04

Change

-15.48 (-2.66)%

Market Cap

USD 61.98B

Volume

0.58M

Average Target Price

USD 640.61 (+12.97%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-10-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.85 (-1.81%)

USD55.27B 26.75 20.98
SGEN Seagen Inc

-2.07 (-1.05%)

USD34.26B N/A N/A
MRNA Moderna, Inc

-4.93 (-6.98%)

USD27.89B N/A N/A
BGNE BeiGene, Ltd

-2.29 (-0.76%)

USD27.13B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-5.15 (-4.29%)

USD26.30B 32.43 29.34
RPRX Royalty Pharma plc

-1.75 (-4.62%)

USD22.99B 33.55 9.19
GMAB Genmab A/S

-1.30 (-3.72%)

USD22.92B 25.74 2.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
BNTX BioNTech SE

-6.41 (-7.64%)

USD19.78B -99,999.99 N/A
INCY Incyte Corporation

-1.36 (-1.54%)

USD19.32B 47.64 35.20

ETFs Containing REGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

-4.72 (-2.96%)

USD0.49B
WELL:LSE HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.33 (-3.23%)

USD3.93M
HERS-B:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.15 (-2.39%)

USD0.07B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+454.43 (+9,728.73%)

USD0.19B
BIOT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.75 %

N/A

USD8.18M
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

-0.15 (-2.42%)

USD0.19B
MINV:LSE iShares Edge MSCI World M.. 0.00 % 0.30 %

-71.00 (-1.82%)

N/A
XDWE:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

-94.50 (-2.16%)

N/A
XDEB:LSE Xtrackers MSCI World Mini.. 0.00 % 0.25 %

-47.50 (-1.82%)

USD0.53B
HWF:CA Middlefield Health & Well.. 0.00 % 0.85 %

-0.07 (-0.58%)

USD0.05B
IQQ0:F iShares Edge MSCI World M.. 0.00 % 0.30 %

-0.91 (-2.10%)

N/A
SXR0:F iShares Edge MSCI World M.. 0.00 % 0.35 %

-0.17 (-2.87%)

N/A
XDEB:F Xtrackers MSCI World Mini.. 0.00 % 0.25 %

-0.53 (-1.84%)

USD0.53B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.08 (-1.59%)

N/A
FTGU:XETRA First Trust US Large Cap .. 0.00 % 0.00 %

-0.77 (-1.76%)

N/A
IQQ0:XETRA iShares Edge MSCI World M.. 0.00 % 0.30 %

-0.78 (-1.81%)

N/A
SXR0:XETRA iShares Edge MSCI World M.. 0.00 % 0.35 %

-0.14 (-2.26%)

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

-1.18 (-2.95%)

USD0.15B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

-0.15 (-1.40%)

USD0.08B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-3.51 (-5.01%)

USD0.21B
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.35 %

N/A

USD0.26B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+1.44 (+4.74%)

USD0.01B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.55 %

-3.06 (-1.95%)

USD1.96B
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

-0.73 (-2.04%)

USD0.01B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

-3.51 (-2.58%)

USD9.52B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.06 %

+4.28 (+8.89%)

USD0.08B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

-0.71 (-2.76%)

USD0.04B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-1.59 (-2.67%)

USD0.22B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
DWPP First Trust Dorsey Wright.. 0.00 % 0.60 %

-0.98 (-3.82%)

USD0.01B
XMS:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

-0.99 (-3.58%)

USD0.06B
XMU:CA iShares MSCI Min Vol USA .. 0.00 % 0.30 %

-1.07 (-1.89%)

USD0.44B
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

-0.60 (-1.40%)

USD0.27B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.45 %

-0.67 (-2.71%)

USD0.06B
XT iShares Exponential Techn.. 0.00 % 0.47 %

-1.40 (-2.83%)

USD2.63B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
HERS:CA Evolve North American Gen.. 0.00 % 0.40 %

N/A

USD3.37M
ENTR ERShares Entrepreneur 30 .. 0.00 % 0.49 %

-0.78 (-3.00%)

USD0.14B
XDEB:XETRA Xtrackers MSCI World Mini.. 0.00 % 0.25 %

-0.52 (-1.80%)

USD0.53B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 51.02% 79% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.02% 79% C+ 86% B
Trailing 12 Months  
Capital Gain 82.33% 78% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 82.33% 78% C+ 88% B+
Trailing 5 Years  
Capital Gain 1.73% 67% D+ 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.73% 67% D+ 42% F
Average Annual (5 Year Horizon)  
Capital Gain 6.32% N/A N/A 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.32% N/A N/A 52% F
Risk Return Profile  
Volatility (Standard Deviation) 36.05% N/A N/A 38% F
Risk Adjusted Return 17.54% N/A N/A 44% F
Market Capitalization 61.98B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 22.47 35% F 42% F
Price/Book Ratio 6.81 30% F 21% F
Price / Cash Flow Ratio 25.50 4% F 13% F
EV/EBITDA 17.37 21% F 43% F
Management Effectiveness  
Return on Equity 31.72% 98% A+ 95% A
Return on Invested Capital 19.11% 93% A 91% A-
Return on Assets 12.71% 98% A+ 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.92 69% D+ 66% D
Short Percent 3.04% 73% C 52% F
Beta 0.50 87% B+ 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.